Merck to Participate at the Morgan Stanley Global Healthcare Conference
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Tech stocks weigh on Wall Street as Iran stalemate lifts oil, yields
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Wall Street indexes slip as oil prices rise, retail results awaited
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Trump threatens to bomb Oman over Iran stance
- U.S. EV market shows signs of bottoming out: Bernstein
BMO Incrementally More Positive on Merck (MRK) as Omarigliptin Met Primary Endpoint in Phase 3
September 16, 2015 2:53 PM EDTBMO Capital affirms Merck (NYSE: MRK) with an Outperform rating and $70 price target following news that omarigliptin, Mercks investigational once-weekly DPP-4 inhibitor in development for adults with type 2 diabetes, achieved its primary efficacy endpoint in a Phase 3 study. Omarigliptin was found to be non-inferior to Mercks once-daily DPP-4 inhibitor, JANUVIA® (sitagliptin), at reducing patients A1C* levels from baseline, with similar A1C reductions achieved in both groups.
Analyst Alex Arfaei commented: Based on impressive data in... More
Merck (MRK) Announces Omarigliptin Phase 3 Met Primary Endpoint in Type 2 Diabetes
September 16, 2015 10:17 AM EDTMerck (NYSE: MRK) announced that omarigliptin, Mercks investigational once-weekly DPP-4 inhibitor in development for adults with type 2 diabetes, achieved its primary efficacy endpoint in a Phase 3 study. Omarigliptin was found to be non-inferior to Mercks once-daily DPP-4 inhibitor, JANUVIA® (sitagliptin), at reducing patients A1C* levels from baseline, with similar A1C... More
